Corpus overview


MeSH Disease

Human Phenotype


There are no transmission terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page

    Psychological consequences of COVID-19 pandemic in Italian MS patients: signs of resilience?

    Authors: Rocco Capuano; Manuela Altieri; Alvino Bisecco; Alessandro d'Ambrosio; Renato Docimo; Daniela Buonanno; Federica Matrone; Federica Giuliano; Gioacchino Tedeschi; Gabriella Santangelo; Antonio Gallo

    doi:10.21203/ Date: 2020-06-04 Source: ResearchSquare

    Background: Anxiety HP, depression and reduction of quality of life (QoL) are common in people with multiple sclerosis MESHD (pwMS). Fear of getting sick from COVID-19, government’s lockdown and the imposed social distancing might have an impact on psychological distress and QoL. Objectives: The aim of our study was to investigate anxiety HP, depression and QoL changes in pwMS during SARS-CoV-2 outbreak and lockdown in Italy.Methods: 67 pwMS with a previous (less than 6 months) neuropsychological evaluation before SARS-CoV-2 outbreak (T0) were re-evaluated at the time of the outbreak and lockdown in Italy (T1). They underwent a clinical and neurological evaluation (at T0) and completed the State-Trait Anxiety HP Inventory (STAI-Y1), the Beck Depression Inventory second edition (BDI-II), and Multiple Sclerosis MESHD Quality of Life-54 (MsQoL-54) at T0 and T1. Bonferroni correction for multiple comparisons was applied.Results: BDI-II and STAI-Y1 scores did not change between T0 and T1, whereas the satisfaction on sexual function subscale of MsQoL-54 was significantly higher at T1 (p<0.001).Conclusions: This is the first study that evaluated mood and QoL levels before and during the lockdown due to COVID-19 pandemic in pwMS. No worsening of anxiety HP and depression levels was found. Contrariwise, some improvements were noted on QoL, the most reliable regarding the sexual satisfaction.

    COVID-19 in Teriflunomide-Treated Patients with Multiple Sclerosis MESHD

    Authors: Amir-Hadi Maghzi; Maria K. Houtchens; Paolo Preziosa; Carolina Ionete; Biljana D Beretich; James M Stankiewicz; Shahamat Tauhid; Ann Cabot; Idanis Berriosmorales; Tamara HW Schwartz; Jacob A Sloane; Mark S Freedman; Massimo Filippi; Howard L Weiner; Rohit Bakshi

    doi:10.21203/ Date: 2020-05-13 Source: ResearchSquare

    The outbreak of a severe acute respiratory syndrome MESHD caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis MESHD (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection MESHD. The patients continued teriflunomide therapy and had self-limiting infection MESHD, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.

    Avoiding COVID-19 Complications with Diabetic Patients Could Be Achieved by Multi-Dose Bacillus Calmette–Guérin Vaccine: A Case Study of Beta Cells Regeneration by Serendipity

    Authors: Bassam M. Ayoub; Eman Ramadan; Nermeen Ashoush; Mariam M. Tadros; Moataz S. Hendy; Mohamed M. Elmazar; Shaker A. Mousa

    id:10.20944/preprints202004.0134.v1 Date: 2020-04-09 Source:

    Diabetes mellitus MESHD Diabetes mellitus HP (DM) is one of the major risk factors for COVID-19 complications as it is one of the chronic immune-compromising conditions especially if patients have uncontrolled diabetes, poor HbA1c &/or irregular blood SERO glucose levels. Diabetic patient’s mortality rates with COVID-19 are higher than cardiovascular or cancer patients. Recently Bacillus Calmette–Guérin (BCG) has shown successful results in reversing diabetes in both rats and clinical trials based on different mechanisms from aerobic glycolysis to Beta cells regeneration. BCG is a multi-face vaccine that has been used extensively in protection from TB and leprosy MESHD and has been repositioned for treatment of bladder cancer, diabetes & multiple sclerosis MESHD. Recently, the COVID-19 epidemiological study confirmed that universal BCG vaccination reduced morbidity and mortality in certain geographical areas. Countries without universal policies of BCG vaccination (Italy, Nederland, USA) have been more severely affected compared to countries with universal and long-standing BCG policies that have shown low numbers of reported COVID-19 cases. Some countries have started clinical trials that included a single dose BCG vaccine as prophylaxis from COVID-19 or an attempt to minimize its side effects. This proposed research aims to use BCG vaccine as a double-edged weapon countering both COVID-19 & diabetes, not only as protection but also as therapeutic vaccination. The work includes a case study of regenerated pancreatic beta cells based on improved C-peptide & PCPRI laboratory findings after BCG vaccination for a 9 years’ patient. The patient was re-vaccinated based on a negative tuberculin test & no scar HP at the site of injection of the 1st BCG vaccination at birth. Furthermore, the authors in the present article described a prospective BCG multi-dose clinical study in full details that they will apply in case of acceptance of their submitted grant & the ethical committee approval. The aim of the clinical study is to check if double dose BCG (4 weeks apart) will show a significant difference in the protection of health care professionals in Egypt. The authors suggest and invite the scientific community to take into consideration the concept of direct BCG re-vaccination (after 4 weeks) because of the reported gene expressions & exaggerated innate immunity consequently. As the diabetic MODY-5 patient (mutation of HNF1B, Val2Leu) was on low dose Riomet® while eliminating insulin gradually, a simple analytical method for metformin assay was recommended to ensure its concentration before use as it is not approved yet by the Egyptian QC labs.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.